Search

Displaying results 6791 - 6800 of 7399 in total
  1. Drug

    Ferrous aspartate

    go.drugbank.com/drugs/DB13220
    Experimental

    The use of ferrous acetate over ferrous sulfate is currently undergoing an investigation by a clinical trial [L5464]. It is also used for dying of fabric or leather and as a wood preservative.

  2. Drug

    TAK-754

    go.drugbank.com/drugs/DB17850
    Investigational

    Developed by Takeda, it is being investigated for the treatment of hemophilia A.[A259831]

  3. Drug

    Troxacitabine

    go.drugbank.com/drugs/DB04961
    Investigational

    Troxacitabine is a nucleoside analog with antineoplastic activity. There has been growing interest in its development for the treatment of patients with refractory lymphoproliferative conditions.

  4. Drug

    Zilebesiran

    go.drugbank.com/drugs/DB18929
    Investigational

    Zilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care

  5. Drug

    Ofloxacin

    go.drugbank.com/drugs/DB01165
    ApprovedInvestigational

    A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

  6. Drug

    AM336

    go.drugbank.com/drugs/DB06563
    Experimental

    Leconotide (development codes CNSB004 and AM336) is an omega-conotoxin peptide known for its analgesic properties, which work by blocking neuronal voltage-sensitive calcium channels.

    Categories: Calcium Channels, N-Type
  7. Drug

    Tanespimycin

    go.drugbank.com/drugs/DB05134
    Investigational

    Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90).

  8. Drug

    2X-121

    go.drugbank.com/drugs/DB16063
    Investigational

    2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the

  9. Drug

    AZD-8186

    go.drugbank.com/drugs/DB15029
    Investigational

    investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by

  10. Drug

    Q-Derp1

    go.drugbank.com/drugs/DB05857
    Experimental

    Q-Derp1 is developed by Cytos Biotechnology as an immunodrug. It is an antigen for the prevention of various major chronic diseases. Derp1 is the dominant allergic protein found in dust mite feces.